Studies found that targeting CXCL12/CXCR4 signaling by an OV expressing CXCR4 antagonist effectively disrupted the tumor vasculature, induced ICD of cancer cells, reversed immunosuppressive TME and improved antitumor immunity, including inhibition of cancer metastasis [86, 87]. This evidence concerns the gene CXCR4 and neoplasm.